Manos Perros

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations · Full text

Standard Deviations, Immunology, Pharmacotherapy +19

Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry

Mike Westby, Caroline Smith‐Burchnell, Julie Mori et al. · Journal of Virology · 2006 · 346 citations

Phenotypic Susceptibility Assays, Immunology, Ccr5 Antagonist +16

Emergence of CXCR4-Using Human Immunodeficiency Virus Type 1 (HIV-1) Variants in a Minority of HIV-1-Infected Patients following Treatment with the CCR5 Antagonist Maraviroc Is from a Pretreatment CXCR4-Using Virus Reservoir

Mike Westby, Marilyn Lewis, Jeannette M. Whitcomb et al. · Journal of Virology · 2006 · 330 citations · Full text

Ccr5 Antagonist Maraviroc, Ccr5 Tropic, Human Retrovirus +11

HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention

Wade Blair, Chris Pickford, S.L. Irving et al. · PLoS Pathogens · 2010 · 296 citations · Full text

Immunology, Molecular Biology, Antiviral Drug +19

Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate

Charles E. Mowbray, Catherine Burt, Romuald Corbau et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 100 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Heterocyclic +12